These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16636022)

  • 1. The value of animal models for drug development in multiple sclerosis.
    Friese MA; Montalban X; Willcox N; Bell JI; Martin R; Fugger L
    Brain; 2006 Aug; 129(Pt 8):1940-52. PubMed ID: 16636022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are current disease-modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?
    Farooqi N; Gran B; Constantinescu CS
    J Neurochem; 2010 Nov; 115(4):829-44. PubMed ID: 20807309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis.
    Steinman L; Zamvil SS
    Trends Immunol; 2005 Nov; 26(11):565-71. PubMed ID: 16153891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.
    Robinson AP; Harp CT; Noronha A; Miller SD
    Handb Clin Neurol; 2014; 122():173-89. PubMed ID: 24507518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research.
    Gold R; Linington C; Lassmann H
    Brain; 2006 Aug; 129(Pt 8):1953-71. PubMed ID: 16632554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis.
    Bolton C
    Inflammopharmacology; 2007 Oct; 15(5):183-7. PubMed ID: 17943249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations.
    Mix E; Meyer-Rienecker H; Zettl UK
    J Neurol; 2008 Dec; 255 Suppl 6():7-14. PubMed ID: 19300954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).
    Constantinescu CS; Farooqi N; O'Brien K; Gran B
    Br J Pharmacol; 2011 Oct; 164(4):1079-106. PubMed ID: 21371012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis.
    Ransohoff RM
    Trends Immunol; 2006 Apr; 27(4):167-8. PubMed ID: 16513422
    [No Abstract]   [Full Text] [Related]  

  • 10. Animal models: Not close enough.
    Rice J
    Nature; 2012 Apr; 484(7393):S9. PubMed ID: 22509510
    [No Abstract]   [Full Text] [Related]  

  • 11. From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development.
    Ben-Nun A; Kaushansky N; Kawakami N; Krishnamoorthy G; Berer K; Liblau R; Hohlfeld R; Wekerle H
    J Autoimmun; 2014 Nov; 54():33-50. PubMed ID: 25175979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the pharmacological control of experimental allergic encephalomyelitis (EAE) and the implications for multiple sclerosis treatment.
    Bolton C
    Mult Scler; 1995 Nov; 1(3):143-9. PubMed ID: 9345444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cop 1 as a candidate drug for multiple sclerosis.
    Teitelbaum D; Arnon R; Sela M
    J Neural Transm Suppl; 1997; 49():85-91. PubMed ID: 9266417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroimmunology of multiple sclerosis and experimental allergic encephalomyelitis.
    Stuerzebecher S; Martin R
    Neuroimaging Clin N Am; 2000 Nov; 10(4):649-68 ,vii-viii. PubMed ID: 11359717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EAE: imperfect but useful models of multiple sclerosis.
    't Hart BA; Gran B; Weissert R
    Trends Mol Med; 2011 Mar; 17(3):119-25. PubMed ID: 21251877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinnamon ameliorates experimental allergic encephalomyelitis in mice via regulatory T cells: implications for multiple sclerosis therapy.
    Mondal S; Pahan K
    PLoS One; 2015; 10(1):e0116566. PubMed ID: 25569428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Expression in Spontaneous Experimental Autoimmune Encephalomyelitis Is Linked to Human Multiple Sclerosis Risk Genes.
    Faber H; Kurtoic D; Krishnamoorthy G; Weber P; Pütz B; Müller-Myhsok B; Weber F; Andlauer TFM
    Front Immunol; 2020; 11():2165. PubMed ID: 33072080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison.
    Dal Canto MC; Melvold RW; Kim BS; Miller SD
    Microsc Res Tech; 1995 Oct; 32(3):215-29. PubMed ID: 8527856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease.
    Kanwar JR
    Curr Med Chem; 2005; 12(25):2947-62. PubMed ID: 16378498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Merits and complexities of modeling multiple sclerosis in non-human primates: implications for drug discovery.
    't Hart BA; Laman JD; Kap YS
    Expert Opin Drug Discov; 2018 May; 13(5):387-397. PubMed ID: 29465302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.